ANAB · NASDAQ
AnaptysBio (ANAB) Stock Price & Fundamentals
AnaptysBio (ANAB) closed at $461.28 on Oct 9, 2026, down 1.12% from the previous close of $466.49.
Share price, past year
1Y +6.07%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $461.28 |
| Sep 30, 2026 | $467.29 |
| Aug 31, 2026 | $462.32 |
| Jul 31, 2026 | $473.84 |
| Jun 30, 2026 | $501.69 |
| May 29, 2026 | $475.95 |
| Apr 30, 2026 | $455.30 |
| Mar 31, 2026 | $440.26 |
| Feb 27, 2026 | $427.46 |
| Jan 30, 2026 | $434.48 |
| Dec 31, 2025 | $442.67 |
| Nov 28, 2025 | $445.55 |
| Oct 31, 2025 | $435.59 |
Key statistics
- Market cap
- $13.39B
- P/E (TTM)
- —
- EPS (TTM)
- −$1.02
- Revenue (TTM)
- $232.39M
- Net income (TTM)
- −$26.79M
- Shares outstanding
- 29M
- Dividend yield
- —
- 52-week range
- $422.90 – $504.05
AnaptysBio's market cap is $13.39B, based on a share price of $461.28 and 29M shares outstanding as of Mar 31, 2026.
Financials
AnaptysBio reported revenue of $234.60M for fiscal 2025, up 157.01% from fiscal 2024.
AnaptysBio reported a net loss of $13.23M in fiscal 2025.
Fiscal 2025 revenue was the highest in the 10 years shown.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $234.60M | +157.0% | −$13.23M | −5.6% | −$0.46 | $19.61M |
| FY2024ended Dec 31, 2024 | $91.28M | +432.0% | −$145.23M | −159.1% | −$5.12 | −$135.70M |
| FY2023ended Dec 31, 2023 | $17.16M | +66.8% | −$163.62M | −953.7% | −$6.08 | −$121.61M |
| FY2022ended Dec 31, 2022 | $10.29M | −83.7% | −$128.72M | −1,251.3% | −$4.57 | −$73.95M |
| FY2021ended Dec 31, 2021 | $63.18M | −15.8% | −$57.80M | −91.5% | −$2.11 | −$47.29M |
| FY2020ended Dec 31, 2020 | $75.00M | +837.5% | −$19.93M | −26.6% | −$0.73 | −$14.73M |
| FY2019ended Dec 31, 2019 | $8.00M | +60.0% | −$97.34M | −1,216.7% | −$3.60 | −$70.32M |
| FY2018ended Dec 31, 2018 | $5.00M | −50.0% | −$61.66M | −1,233.1% | −$2.50 | −$49.57M |
| FY2017ended Dec 31, 2017 | $10.00M | −40.1% | −$30.07M | −300.7% | −$1.52 | −$19.73M |
| FY2016ended Dec 31, 2016 | $16.68M | — | −$4.26M | −25.5% | −$1.62 | −$9.08M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q1 FY2026ended Mar 31, 2026 | $25.56M | −$52.88M | −$1.84 |
| Q4 FY2025ended Dec 31, 2025 | $108.25M | $49.61M | $1.64 |
| Q3 FY2025ended Sep 30, 2025 | $76.32M | $15.11M | $0.52 |
| Q2 FY2025ended Jun 30, 2025 | $22.26M | −$38.63M | −$1.34 |
| Q1 FY2025ended Mar 31, 2025 | $27.77M | −$39.33M | −$1.28 |
| Q4 FY2024ended Dec 31, 2024 | $43.11M | −$21.78M | −$0.63 |
| Q3 FY2024ended Sep 30, 2024 | $30.02M | −$32.85M | −$1.14 |
| Q2 FY2024ended Jun 30, 2024 | $10.97M | −$46.66M | −$1.71 |
Company profile
- Name
- AnaptysBio, Inc.
- Ticker
- ANAB
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 10770 Wateridge Circle, Suite 210, San Diego, CA 92121
- Incorporated in
- DE
- Fiscal year ends
- June
- SEC CIK
- 0001370053
Recent SEC filings
- Sep 21, 2026
- Aug 11, 2026
- Jul 30, 2026
- Jun 22, 2026
- May 29, 2026
- May 21, 2026
- May 12, 2026
- May 12, 2026
Frequently asked questions
What is AnaptysBio's stock price?
AnaptysBio (ANAB) closed at $461.28 on Oct 9, 2026, down 1.12% from the previous close of $466.49.
What is AnaptysBio's market cap?
AnaptysBio's market cap is $13.39B, based on a share price of $461.28 and 29M shares outstanding as of Mar 31, 2026.
How much revenue does AnaptysBio make?
AnaptysBio reported revenue of $234.60M for fiscal 2025, up 157.01% from fiscal 2024.
Does AnaptysBio pay a dividend?
AnaptysBio's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from AnaptysBio, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures